(AIP) Arteris - Overview
Stock: NoC IP, Integration Software, Consulting
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 78.7% |
| Relative Tail Risk | -16.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.86 |
| Alpha | 27.09 |
| Character TTM | |
|---|---|
| Beta | 2.080 |
| Beta Downside | 2.030 |
| Drawdowns 3y | |
|---|---|
| Max DD | 54.48% |
| CAGR/Max DD | 0.66 |
Description: AIP Arteris December 28, 2025
Arteris Inc. (NASDAQ:AIP) designs and licenses semiconductor-system IP that orchestrates on-chip communication for System-on-Chip (SoC) and chiplet architectures. Its product portfolio includes the FlexGen/FlexNoC/FlexWay non-coherent Network-on-Chip (NoC) family, the cache-coherent Ncore NoC, the CodaCache last-level cache, and integration-automation tools such as Magillem and CSRCompiler. The company also monetizes professional services, licensing, and support across automotive, communications, enterprise computing, consumer electronics, and industrial markets.
Key market signals that could affect Arteris’ growth trajectory include: (1) the accelerating adoption of chiplet-based designs, which the industry estimates will capture ≈ 30 % of new high-performance SoC launches by 2026, expanding the addressable TAM for NoC IP; (2) its FY 2024 revenue of ≈ $115 million, reflecting a ≈ 22 % YoY increase driven largely by automotive and data-center customers; and (3) a rising R&D intensity, with R&D expenses representing ≈ 15 % of revenue, underscoring the need to stay ahead of competing IP providers such as Arm and Synopsys. These drivers are balanced against macro-level semiconductor cyclicality and the company’s reliance on a limited number of large licensees.
For a deeper quantitative assessment, the ValueRay platform provides a concise, data-driven view of Arteris’ valuation metrics and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -34.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 1.47 > 1.0 |
| NWC/Revenue: -12.48% < 20% (prev 10.74%; Δ -23.22% < -1%) |
| CFO/TA 0.01 > 3% & CFO 932.0k > Net Income -34.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (42.7m) vs 12m ago 8.77% < -2% |
| Gross Margin: 89.98% > 18% (prev 0.89%; Δ 8908 % > 0.5%) |
| Asset Turnover: 64.18% > 50% (prev 56.02%; Δ 8.16% > 0%) |
| Interest Coverage Ratio: -159.2 > 6 (EBITDA TTM -25.9m / Interest Expense TTM 184.0k) |
Altman Z'' -8.79
| A: -0.08 (Total Current Assets 58.5m - Total Current Liabilities 66.8m) / Total Assets 107.7m |
| B: -1.51 (Retained Earnings -163.1m / Total Assets 107.7m) |
| C: -0.29 (EBIT TTM -29.3m / Avg Total Assets 102.7m) |
| D: -1.37 (Book Value of Equity -162.8m / Total Liabilities 119.2m) |
| Altman-Z'' Score: -8.79 = D |
Beneish M -2.64
| DSRI: 1.54 (Receivables 16.5m/8.90m, Revenue 65.9m/54.7m) |
| GMI: 0.99 (GM 89.98% / 89.34%) |
| AQI: 1.25 (AQ_t 0.38 / AQ_t-1 0.30) |
| SGI: 1.20 (Revenue 65.9m / 54.7m) |
| TATA: -0.33 (NI -34.4m - CFO 932.0k) / TA 107.7m) |
| Beneish M-Score: -2.64 (Cap -4..+1) = A |
What is the price of AIP shares?
Over the past week, the price has changed by -0.53%, over one month by -15.07%, over three months by +0.27% and over the past year by +53.29%.
Is AIP a buy, sell or hold?
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AIP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.3 | 28.9% |
| Analysts Target Price | 19.3 | 28.9% |
| ValueRay Target Price | 16.8 | 12.5% |
AIP Fundamental Data Overview January 31, 2026
P/B = 56.0391
Revenue TTM = 65.9m USD
EBIT TTM = -29.3m USD
EBITDA TTM = -25.9m USD
Long Term Debt = 624.0k USD (from longTermDebt, last quarter)
Short Term Debt = 2.80m USD (from shortTermDebt, last quarter)
Debt = 6.86m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -10.7m USD (from netDebt column, last quarter)
Enterprise Value = 651.9m USD (684.1m + Debt 6.86m - CCE 39.1m)
Interest Coverage Ratio = -159.2 (Ebit TTM -29.3m / Interest Expense TTM 184.0k)
EV/FCF = -1000.0x (Enterprise Value 651.9m / FCF TTM -372.0k)
FCF Yield = -0.06% (FCF TTM -372.0k / Enterprise Value 651.9m)
FCF Margin = -0.56% (FCF TTM -372.0k / Revenue TTM 65.9m)
Net Margin = -52.25% (Net Income TTM -34.4m / Revenue TTM 65.9m)
Gross Margin = 89.98% ((Revenue TTM 65.9m - Cost of Revenue TTM 6.61m) / Revenue TTM)
Gross Margin QoQ = 89.86% (prev 89.44%)
Tobins Q-Ratio = 6.05 (Enterprise Value 651.9m / Total Assets 107.7m)
Interest Expense / Debt = 0.71% (Interest Expense 49.0k / Debt 6.86m)
Taxrate = 21.0% (US default 21%)
NOPAT = -23.1m (EBIT -29.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.88 (Total Current Assets 58.5m / Total Current Liabilities 66.8m)
Debt / Equity = -0.60 (negative equity) (Debt 6.86m / totalStockholderEquity, last quarter -11.4m)
Debt / EBITDA = 0.41 (negative EBITDA) (Net Debt -10.7m / EBITDA -25.9m)
Debt / FCF = 28.65 (negative FCF - burning cash) (Net Debt -10.7m / FCF TTM -372.0k)
Total Stockholder Equity = -6.25m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.53% (Net Income -34.4m / Total Assets 107.7m)
RoE = 551.4% (negative equity) (Net Income TTM -34.4m / Total Stockholder Equity -6.25m)
RoCE = 521.0% (negative capital employed) (EBIT -29.3m / Capital Employed (Equity -6.25m + L.T.Debt 624.0k))
RoIC = -2606 % (out of range, set to none) (NOPAT -23.1m / Invested Capital 888.0k)
WACC = 13.45% (E(684.1m)/V(690.9m) * Re(13.58%) + D(6.86m)/V(690.9m) * Rd(0.71%) * (1-Tc(0.21)))
Discount Rate = 13.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.20%
Fair Price DCF = unknown (Cash Flow -372.0k)
EPS Correlation: 51.26 | EPS CAGR: 41.94% | SUE: 4.0 | # QB: 1
Revenue Correlation: 80.66 | Revenue CAGR: 11.86% | SUE: 1.26 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.06 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.14 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+61.0% | Growth Revenue=+20.2%